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Summary. Colorectal cancer (CRC) is one of the most 
common causes of cancer death in the developed world. 
Although the primary treatment for CRC is surgical, 
disease relapse due to minimal residual disease (MRD) 
following apparently curative surgery occurs in up to 
fifty percent of patients. Most patients who develop 
overt metastases beyond the regional lymph nodes 
eventually die of the disease. At present adjuvant 
chemotherapy is used to improve survival in patients 
with metastases to regional lymph nodes demonstrated 
by routine histopathology with no other evidence of 
spread. The ability to identify metastatic disease at an 
earlier stage could be of considerable benefit in directing 
adjuvant therapy to patients at high risk of relapse who 
are not identified by current methods. Several techniques 
have been developed for the detection of MRD, 
including immunohistochemical and molecular methods, 
however their role in clinical practise is not yet 
established. The purpose of this paper is to review these 
techniques and their potential clinical use in the 
management of CRC. 
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Introduction 
Staging of colorectal cancer 
Disease stage is the most important predictor of 
outcome after surgery for colorectal cancer (CRC). The 
Dukes staging system for rectal cancer (Dukes, 1932) 
identified the essential elements of penetration through 
the bowel wall and the presence of lymph node 
metastases. Since that time many modifications and sub- 
classifications have been proposed, all with the aim of 
improving prognostic accuracy (Table 1). However 
these staging systems have resulted in only limited 
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improvements in prognostic accuracy when compared 
with the original Dukes system (Onodera et al., 1989). 
The importance of accurate staging 
Prognostic information is most useful when it 
enables identification of patients who can be treated 
more aggressively with the expectation of improving 
outcome (Jass, 1995). In CRC the advent of effective 
adjuvant therapy in histologically proven lymph node 
positive disease has heightened the importance of this 
prognostic indicator (NIH consensus conference, 1990). 
However, the problem remains that up to 40% of 
patients with histologically node negative CRC 
eventually die of recurrent disease (Newland et al., 
1987). This is thought to be due to the presence of 
minimal residual disease (MRD) at the time of surgery, 
which is not detected by conventional histological or 
imaging techniques (Finlay and McCardle, 1986). The 
need for more sensi t ive and specif ic  prognostic 
information is therefore real because adjuvant therapy 
could be targeted more effectively to those patients with 
the highest likelihood of benefit. 
New prognostic markers 
In recent years much work has been done on CRC 
trying to develop new prognostic markers utilising 
research which has broadened the understanding of basic 
tumour biology (Fielding, 1998). Efforts were made in 
1995 by the College of American Pathologists to review 
the available work and assess its potential clinical 
applicability (Fielding and Pettigrew, 1995). However, 
even since that time over 1000 citations can be found on 
a Medline search with reference to CRC and the newer 
biological variables.  These include markers  of 
differentiation (van Belzen et al., 1998), proliferation 
(Shepherd et al., 1988; Mayer et al., 1993), angiogenesis 
(Frank et al., 1995; Kumar et al., 1998), metastatic 
potential (Dorudi et al., 1993; Tanabe et al., 1993) and 
the presence or absence of tumour suppressor genes 
(Yamaguchi et al., 1992; Poller et al., 1997). Although 
some of the newer markers  have proved to have 








